Related references
Note: Only part of the references are listed.Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non-small-cell lung cancer: The MILES-2P studies
Cesare Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST)
Jean-Yves Douillard et al.
JOURNAL OF THORACIC ONCOLOGY (2007)
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes
Jing Li et al.
CLINICAL CANCER RESEARCH (2007)
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10
Carmela Pepe et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II clinical trial of chemotherapy-naive patients >= 70 years of age treated with erlotinib for advanced non-small-cell lung cancer
David M. Jackman et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program
Matthew J. Hayat et al.
ONCOLOGIST (2007)
Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase II study
Giuseppe Giaccone et al.
CLINICAL CANCER RESEARCH (2006)
Elderly patients benefit from second-line cytotoxic chemotherapy: A subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer
Glen J. Weiss et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21
Andrea Bezjak et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Neglected and underrepresented subpopulations: Elderly and performance status 2 patients with advanced-stage non-small-cell lung cancer
Corey J. Langer
CLINICAL LUNG CANCER (2006)
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer
Tania Cufer et al.
ANTI-CANCER DRUGS (2006)
Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers
J Ling et al.
DRUG METABOLISM AND DISPOSITION (2006)
Chemotherapy for elderly patients with non-small cell lung cancer - A review of the evidence
C Gridelli et al.
CHEST (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Erlotinib in lung cancer - Molecular and clinical predictors of outcome
MS Tsao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Postoperative adjuvant cisplatin, vindesine, plus uracil-tegafur chemotherapy increased survival of patients with completely resected p-stage I non-small cell lung cancer
M Imaizumi
LUNG CANCER (2005)
Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel
C Gridelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: The Cancer and Leukemia Group B (study 9730)
RC Lilenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The influence of age and sex on the clearance of cytochrome P450 3A substrates
MM Cotreau et al.
CLINICAL PHARMACOKINETICS (2005)
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
N Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
F Cappuzzo et al.
BRITISH JOURNAL OF CANCER (2004)
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
C Gridelli et al.
BRITISH JOURNAL OF CANCER (2003)
Long-term trends in cancer mortality in the United States, 1930-1998
PA Wingo et al.
CANCER (2003)
Participation of patients 65 years of age or older in cancer clinical trials
JH Lewis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chemotherapy for elderly patients with advanced non-small-cell lung cancer:: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial
C Gridelli et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme
AM Stark et al.
ZENTRALBLATT FUR NEUROCHIRURGIE (2003)
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
JH Schiller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial
K Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
